156672-71-8

Upstream product

• 94-09-7 p-aminoethylbenzoate 
• 22312-82-9 2-(chloromethyl)-3-(4-methoxyphenyl)quinazolin-4(3H)-one 

Downstream Products

• 116270-62-3 C₃₁H₂₈N₆O₄S 
• 116270-68-9 C₃₀H₂₅BrN₆O₃S 
• 116270-65-6 C₃₀H₂₅ClN₆O₃S 
• 116270-59-8 C₃₁H₂₈N₆O₃S 
• 116270-76-9 3-(4-Methoxy-phenyl)-2-({4-[5-(4-methoxy-phenylamino)-[1,3,4]thiadiazol-2-yl]-phenylamino}-methyl)-3H-quinazolin-4-one 
• 116270-82-7 2-({4-[5-(4-Bromo-phenylamino)-[1,3,4]thiadiazol-2-yl]-phenylamino}-methyl)-3-(4-methoxy-phenyl)-3H-quinazolin-4-one 
• 116270-95-2 2-({4-[5-(4-Bromo-phenylamino)-[1,3,4]oxadiazol-2-yl]-phenylamino}-methyl)-3-(4-methoxy-phenyl)-3H-quinazolin-4-one 
• 116270-79-2 2-({4-[5-(4-Chloro-phenylamino)-[1,3,4]thiadiazol-2-yl]-phenylamino}-methyl)-3-(4-methoxy-phenyl)-3H-quinazolin-4-one 
• 116270-92-9 2-({4-[5-(4-Chloro-phenylamino)-[1,3,4]oxadiazol-2-yl]-phenylamino}-methyl)-3-(4-methoxy-phenyl)-3H-quinazolin-4-one 
• 116270-57-6 N¹--N⁴-phenylthiosemicarbazide 
• 116270-73-6 3-(4-Methoxy-phenyl)-2-{[4-(5-p-tolylamino-[1,3,4]thiadiazol-2-yl)-phenylamino]-methyl}-3H-quinazolin-4-one 
• 116270-87-2 3-(4-Methoxy-phenyl)-2-{[4-(5-p-tolylamino-[1,3,4]oxadiazol-2-yl)-phenylamino]-methyl}-3H-quinazolin-4-one 
• 116270-70-3 3-(4-Methoxy-phenyl)-2-{[4-(5-phenylamino-[1,3,4]thiadiazol-2-yl)-phenylamino]-methyl}-3H-quinazolin-4-one 
• 116270-84-9 3-(4-Methoxy-phenyl)-2-{[4-(5-phenylamino-[1,3,4]oxadiazol-2-yl)-phenylamino]-methyl}-3H-quinazolin-4-one 

Relevant academic research and scientific papers

Synthesis and Pharmacological Evaluation of N1--N4-arylthiosemicarbazides and 2-Arylamino-5--1,3,4-thiadiazoles/oxadiazoles as Oral Hypoglycemic Agents

A series of 2-arylamino-5--1,3,4-thiadiazoles/oxadiazoles (III/IV) have been synthesised from N1--N4-arylthiosemicarbazides (II) by treatment with conc. sulphuric acid or mercuric oxide.The thiosemicarbazides (II), in turn, have been prepared by refluxing 2--3-arylquinazolin-4(3H)-one (I) with various aryl isothiocyanates in abs. ethanol.A few of these compounds when tested on rats at an oral dose of 250 mg/kg, reduced the blood sugar to about 25 percent.